Hexter Joshua 4

What Happened
Joshua Hexter, Chief Operating Officer and Chief Business Officer of Oramed Pharmaceuticals (ORMP), sold 137,000 shares in an open‑market sale on July 1, 2026 for a weighted average price of $4.46, generating $611,431. On July 2, 2026 he exercised 50,000 stock options at $3.69 per share (total cost $184,500), and the filing also shows a related disposition of 50,000 shares at $0.00 tied to the same derivative transaction.

Key Details

• Sale: 137,000 shares on 2026-07-01, weighted average price $4.46, total proceeds $611,431. Price range across trades: $4.255–$4.7652 (per filing footnote).
• Option exercise: 50,000 shares acquired on 2026-07-02 at $3.69 each, total $184,500.
• Zero-dollar disposition: 50,000 shares reported disposed at $0.00 on 2026-07-02 (reported in the same derivative transaction).
• 10b5-1 plan: The July 1 sale was made under a Rule 10b5-1 trading plan adopted March 30, 2026.
• Vesting background: The options referenced vested in 16 equal installments of 6,250 shares beginning Nov 1, 2019 (per footnote).
• Shares owned after transaction: Not disclosed in the provided filing.
• Filing date: Report filed July 2, 2026 (reporting period listed as July 1, 2026).

Context
The primary action here is a scheduled sale under a 10b5-1 plan, which is generally a pre‑set plan for selling shares rather than an ad hoc sale. The option exercise resulted in 50,000 shares acquired for cash; the matching 50,000‑share disposition recorded at $0.00 commonly reflects shares withheld or surrendered to cover exercise costs or tax withholding in a cashless exercise, though the filing lists it as a derivative disposition rather than an open‑market sale. These filings are factual records of transactions and do not, by themselves, indicate the insider’s motivations.